EA202190955A1 - Способы снижения агрегации биспецифических антител - Google Patents
Способы снижения агрегации биспецифических антителInfo
- Publication number
- EA202190955A1 EA202190955A1 EA202190955A EA202190955A EA202190955A1 EA 202190955 A1 EA202190955 A1 EA 202190955A1 EA 202190955 A EA202190955 A EA 202190955A EA 202190955 A EA202190955 A EA 202190955A EA 202190955 A1 EA202190955 A1 EA 202190955A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- methods
- bispecific antibodies
- reducing aggregation
- aggregation
- reducing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Изобретение, раскрытое в данном документе, относится к способам снижения агрегации биспецифических антител, например снижения агрегации конструкций на основе биспецифического антитела-рекрутера Т-клеток (BiTE), в результате хранения в условиях заморозки с помощью выдерживания антител при определенных температурах после размораживания.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862739542P | 2018-10-01 | 2018-10-01 | |
PCT/US2019/053462 WO2020072306A1 (en) | 2018-10-01 | 2019-09-27 | Methods for reducing aggregation of bispecific antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202190955A1 true EA202190955A1 (ru) | 2021-08-17 |
Family
ID=70055398
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202190955A EA202190955A1 (ru) | 2018-10-01 | 2019-09-27 | Способы снижения агрегации биспецифических антител |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP3860567A4 (ru) |
JP (1) | JP2022512569A (ru) |
KR (1) | KR20210070314A (ru) |
CN (1) | CN112789028A (ru) |
AU (1) | AU2019351715A1 (ru) |
BR (1) | BR112021006220A2 (ru) |
CA (1) | CA3112655A1 (ru) |
CL (1) | CL2021000827A1 (ru) |
EA (1) | EA202190955A1 (ru) |
IL (1) | IL281621A (ru) |
MA (1) | MA53831A (ru) |
MX (1) | MX2021003628A (ru) |
SG (1) | SG11202102995PA (ru) |
WO (1) | WO2020072306A1 (ru) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4200333A1 (en) * | 2020-08-24 | 2023-06-28 | Amgen Inc. | Pharmaceutical formulation comprising a bite, bispecific antibody, and methionine |
WO2022060878A1 (en) * | 2020-09-16 | 2022-03-24 | Amgen Inc. | Methods for treating prostate cancer |
EP4214233A1 (en) * | 2020-09-16 | 2023-07-26 | Amgen Inc. | Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer |
CN117377695A (zh) * | 2021-06-30 | 2024-01-09 | 安进公司 | 冻干制剂的重构方法 |
WO2024059675A2 (en) * | 2022-09-14 | 2024-03-21 | Amgen Inc. | Bispecific molecule stabilizing composition |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX359384B (es) * | 2011-10-11 | 2018-09-25 | Genentech Inc | Conjunto mejorado de anticuerpos bisespecificos. |
TR201809507T4 (tr) * | 2012-11-06 | 2018-07-23 | Bayer Pharma AG | Bispesifik T-hücresi bağlayıcıları (BİTE'ler) için formülasyon. |
TWI679019B (zh) * | 2013-04-29 | 2019-12-11 | 法商賽諾菲公司 | 抗il-4/抗il-13之雙特異性抗體調配物 |
ES2974895T3 (es) * | 2014-05-07 | 2024-07-02 | Takeda Pharmaceuticals Co | Formulación líquida que comprende un compuesto neutralizante de GM-CSF |
WO2016036678A1 (en) * | 2014-09-02 | 2016-03-10 | Medimmune, Llc | Formulations of bispecific antibodies |
MX2018008300A (es) * | 2016-01-13 | 2018-09-21 | Genmab As | Formulacion para anticuerpo y conjugado de farmaco del mismo. |
TWI797073B (zh) * | 2016-01-25 | 2023-04-01 | 德商安美基研究(慕尼黑)公司 | 包含雙特異性抗體建構物之醫藥組合物 |
LT3411404T (lt) * | 2016-02-03 | 2022-12-27 | Amgen Research (Munich) Gmbh | Psma ir cd3 bispecifiniai, t ląsteles aktyvuojantys antikūno konstruktai |
US11918650B2 (en) * | 2017-05-05 | 2024-03-05 | Amgen Inc. | Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration |
CA3082507A1 (en) * | 2017-12-11 | 2019-06-20 | Amgen Inc. | Continuous manufacturing process for bispecific antibody products |
-
2019
- 2019-09-27 SG SG11202102995PA patent/SG11202102995PA/en unknown
- 2019-09-27 KR KR1020217012083A patent/KR20210070314A/ko unknown
- 2019-09-27 JP JP2021517615A patent/JP2022512569A/ja active Pending
- 2019-09-27 MA MA053831A patent/MA53831A/fr unknown
- 2019-09-27 AU AU2019351715A patent/AU2019351715A1/en active Pending
- 2019-09-27 WO PCT/US2019/053462 patent/WO2020072306A1/en unknown
- 2019-09-27 CA CA3112655A patent/CA3112655A1/en active Pending
- 2019-09-27 BR BR112021006220A patent/BR112021006220A2/pt unknown
- 2019-09-27 MX MX2021003628A patent/MX2021003628A/es unknown
- 2019-09-27 EA EA202190955A patent/EA202190955A1/ru unknown
- 2019-09-27 EP EP19869416.8A patent/EP3860567A4/en active Pending
- 2019-09-27 CN CN201980064486.6A patent/CN112789028A/zh active Pending
-
2021
- 2021-03-18 IL IL281621A patent/IL281621A/en unknown
- 2021-04-01 CL CL2021000827A patent/CL2021000827A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CL2021000827A1 (es) | 2021-10-15 |
EP3860567A1 (en) | 2021-08-11 |
WO2020072306A1 (en) | 2020-04-09 |
KR20210070314A (ko) | 2021-06-14 |
JP2022512569A (ja) | 2022-02-07 |
MX2021003628A (es) | 2021-05-27 |
AU2019351715A1 (en) | 2021-04-22 |
EP3860567A4 (en) | 2022-07-06 |
IL281621A (en) | 2021-05-31 |
CN112789028A (zh) | 2021-05-11 |
SG11202102995PA (en) | 2021-04-29 |
MA53831A (fr) | 2022-01-05 |
CA3112655A1 (en) | 2020-04-09 |
BR112021006220A2 (pt) | 2021-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202190955A1 (ru) | Способы снижения агрегации биспецифических антител | |
CO2018001149A2 (es) | Anticuerpos monoclonales contra bcma | |
AU2018366199A1 (en) | Bispecific and monospecific antibodies using novel anti-PD-1 sequences | |
PE20191812A1 (es) | Compuestos y metodos para la reduccion celular especifica de tumor | |
EP4257613A3 (en) | Bispecific checkpoint inhibitor antibodies | |
AR113342A1 (es) | Anticuerpos específicos cd47 / pd-l1 | |
CL2017003195A1 (es) | Anticuerpos madurados por afinidad y humanizados para fcrh5 y métodos para su uso. | |
AR096839A1 (es) | Proceso mejorado para la producción de anticuerpos monoclonales | |
MX2021009926A (es) | Agonistas il-2rbeta-selectivos en combinacion con un anticuerpo anti-ctla-4 o un anticuerpo anti-pd-1. | |
EA201891983A8 (ru) | Комбинированная терапия антителами к cd73 | |
CL2017000545A1 (es) | Anticuerpos anti-her2 e inmunoconjugados | |
EA201500995A1 (ru) | Биспецифические антитела, специфические в отношении fap и dr5, антитела, специфические в отношении dr5, и способы их применения | |
CU20190100A7 (es) | Anticuerpos biespecíficos y método de fabricación de los mismos | |
CL2017003255A1 (es) | Terapias de combinación para males hematologicos con anticuerpos anti-cd38 e inhibidores de survivin. | |
CL2016000221A1 (es) | Anticuerpos anti-fgfr2iiib afucosilados. | |
AR104809A1 (es) | Anticuerpos anti-cd40 y usos de los mismos | |
PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
EA201391389A1 (ru) | Кристаллы антител против склеростина и составы на их основе | |
EA201391540A1 (ru) | Агонисты fgfr1 и способы их применения | |
BR112017009976A2 (pt) | gado de leite híbrido e sistemas para maximizar vantagem híbrida | |
MX2023006416A (es) | Anticuerpos, usos y metodos. | |
PH12020551948A1 (en) | Monospecific and multispecific anti-tmeff2 antibodies and their uses | |
UY36255A (es) | Compuestos sustituidos por halógeno novedosos | |
EA201890739A1 (ru) | Анти-s100a8 для лечения лейкемии | |
PE20190415A1 (es) | Anticuerpos anti-basigin humanizados y uso de los mismos |